1. Home
  2. TALO vs TNDM Comparison

TALO vs TNDM Comparison

Compare TALO & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Talos Energy Inc.

TALO

Talos Energy Inc.

HOLD

Current Price

$11.39

Market Cap

1.8B

Sector

Energy

ML Signal

HOLD

Logo Tandem Diabetes Care Inc.

TNDM

Tandem Diabetes Care Inc.

HOLD

Current Price

$20.90

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TALO
TNDM
Founded
2011
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical/Dental Instruments
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
TALO
TNDM
Price
$11.39
$20.90
Analyst Decision
Buy
Buy
Analyst Count
5
17
Target Price
$14.30
$24.06
AVG Volume (30 Days)
1.7M
1.4M
Earning Date
02-24-2026
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,872,554,000.00
$1,007,001,000.00
Revenue This Year
N/A
$8.59
Revenue Next Year
N/A
$10.19
P/E Ratio
N/A
N/A
Revenue Growth
0.06
17.87
52 Week Low
$6.23
$9.98
52 Week High
$12.20
$37.93

Technical Indicators

Market Signals
Indicator
TALO
TNDM
Relative Strength Index (RSI) 56.67 44.92
Support Level $10.33 $20.29
Resistance Level $11.07 $23.95
Average True Range (ATR) 0.36 0.99
MACD -0.00 -0.33
Stochastic Oscillator 84.44 16.51

Price Performance

Historical Comparison
TALO
TNDM

About TALO Talos Energy Inc.

Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Share on Social Networks: